Directory of Global Cancer Vaccine Partnership Terms and Agreements 2010-2021 – ResearchAndMarkets.com
DUBLIN – (COMMERCIAL THREAD)–The “Terms and Agreements for Global Partnership for Cancer Vaccines 2010-2021” the report was added to ResearchAndMarkets.com offer.
The Global Cancer Vaccine Partnering Terms and Agreements 2010-2021 report provides full access to available offerings and contract documents for over 320 cancer vaccine offerings.
This report provides details on the latest cancer vaccine deals announced in the life sciences since 2010.
The report presents the reader with a comprehensive review of cancer vaccine deal trends, key players, most important values, and deal financial data, helping to understand how, why, and under what terms companies are closing. cancer vaccine partnership agreements.
The report presents the values of the terms of financial agreements for cancer vaccine agreements, listing by aggregate value, upfront payments, milestone payments, and royalties, allowing readers to analyze and compare the financial value of the agreements.
The central section of the report explores the key negotiators in the area of the cancer vaccine partnership; Major trade values and the most active cancer vaccine trading companies are reported, allowing the reader to see who is successful in this dynamic trading market.
One of the highlights of the report is that over 320 online tender dossiers for actual cancer vaccine offers, as disclosed by the parties to the case, are included towards the end of the report in a format directory – by AZ company, stage of development, type of business, therapeutic orientation and type of technology – it’s easy to reference. Each transaction record in the report is linked via a web link to an online version of the transaction.
Additionally, when available, records include contractual documents as submitted to the Securities Exchange Commission by the companies and their partners. While many companies research payment term details, the devil is in the detail of triggering payments – contract documents provide that insight where press releases and databases do not.
The report also includes numerous tables and figures that illustrate trends and activities in cancer vaccine partnership and negotiation since 2010.
In conclusion, this report provides everything a potential negotiator needs to know about partnering in the research, development and commercialization of cancer vaccine technologies and products.
The 2010-2021 Global Cancer Vaccine Partnership Terms and Agreements provide the reader with the following key benefits:
In-depth understanding of cancer vaccine agreement trends since 2010
Access to title, advance, milestone and royalty data
Detailed access to actual cancer vaccine contracts signed by major biopharmaceutical companies
Identify the most active cancer vaccine negotiators since 2010
Overview of terms included in a cancer vaccine partnership agreement, with concrete examples
Understand the key terms of agreements that companies have agreed to in previous agreements
Undertake due diligence to assess the adequacy of the terms of your proposed agreement for partner companies
The available offers are listed by:
Company from A to Z
Stage of development at signing
Component type of the agreement
Specific therapeutic target
Type of technology
The analysis of actual contractual agreements makes it possible to assess the following elements:
What are the specific rights granted or opted out?
What is actually granted by the agreement to the partner company?
What exclusivity is granted?
What is the payment structure for the transaction?
How are sales sand payments verified?
How long is the agreement?
How are the key terms of the agreement defined?
How are IPRs managed and held?
Who is responsible for marketing?
Who is responsible for development, sourcing and manufacturing?
How is confidentiality and publication managed?
How to resolve disputes?
Under what conditions can the deal be terminated?
What happens in the event of a change of owner?
What sub-licensing and subcontracting arrangements have been agreed?
What standard clauses does the company insist on?
What standard clauses seem to differ from partner to partner or from type of agreement to type of agreement?
What jurisdiction does the company insist on for the law of agreements?
Main topics covered:
Chapter 1 Introduction
Chapter 2 – Trends in the negotiation of cancer vaccines
2.2. Partnership for a cancer vaccine over the years
2.3. Most Active Cancer Vaccine Negotiators
2.4. Cancer vaccine partnerships by type of agreement
2.5. Cancer vaccine partnership by therapeutic area
2.6. Terms of Agreement for Cancer Vaccine Partnership
2.6.1 Key values of the cancer vaccine partnership
2.6.2 Upfront payments of the cancer vaccine agreement
2.6.3 Milestone Payments Related to Cancer Vaccine Agreement
2.6.4 Cancer vaccine royalty rate
Chapter 3 – The main cancer vaccine offers
3.2. Best cancer vaccine deals by value
Chapter 4 – The Most Active Cancer Vaccine Negotiators
4.2. Most Active Cancer Vaccine Negotiators
4.3. Profiles of the most active Cancer Vaccine partner companies
Chapter 5 – Cancer vaccine contract negotiation directory
5.2. Cancer vaccine contract negotiation directory
Chapter 6 – Cancer Vaccines Negotiations by Technology Type
Chapter 7 – Partner Resource Center
7.1. Online partnership
7.2. Partnership events
7.3. Further reading on negotiation
Annex 1 – Cancer vaccine offers by AZ company
Annex 2 – Cancer vaccine offerings by stage of development
Appendix 3 – Cancer vaccine offers by type of offer
Purchase of assets
Purchase of shares
Appendix 4 – Offers of cancer vaccines by therapeutic area
Annex 5 – Definitions of types of transactions
For more information on this report, visit https://www.researchandmarkets.com/r/j4s1po